Even if cardiovascular protection seems to be a class effect, the suspected risk of worsening of diabetic retinopathy is still in need of clarification.32 The risk of pancreatitis and cholecystitis is now largely considered refuted, but long-term data are lacking for Liraglutide and other GLP1 receptor agonists for the treatment of obesity. Here, GLP1R is linked to obesity disorder.